Investment Highlights - The company, China Traditional Chinese Medicine (00570), is given a neutral rating with a target price of HKD 2.40, corresponding to P/E ratios of 34.5 and 16.3 for 2026 and 2027 respectively [1] - There is increasing policy support for the development of the traditional Chinese medicine industry, with the State Council issuing measures to accelerate its growth, which is expected to enhance the traditional Chinese medicine service system [1] - The company has a solid layout in the traditional Chinese medicine industry chain, currently undergoing a restructuring phase, focusing on core products like traditional Chinese medicine formula granules and expanding into various segments [1] Business Strategy - The company is actively engaged in marketing reforms and business restructuring to adapt to policy impacts such as centralized procurement, aiming for collaborative development across different segments [1][2] - The company is enhancing its technological innovation system to address industry challenges, focusing on the development of innovative traditional Chinese medicines and secondary development of existing products [1] Market Outlook - The market is concerned about potential profit declines due to centralized procurement; however, the company is optimistic about controlling expense ratios through marketing reforms and evidence-based medical research [2] - The company forecasts EPS of -0.11, 0.06, and 0.13 for 2025 to 2027, with current stock price corresponding to P/E ratios of 31.0 and 14.7 for 2026 and 2027, indicating an 11.1% upside potential [2]

Core Viewpoint - CICC has initiated coverage on China Traditional Chinese Medicine (00570) with a neutral rating and a target price of HKD 2.40, corresponding to 34.5x and 16.3x P/E for 2026 and 2027 respectively [1] Group 1: Policy Support - The government is increasingly supporting the development of the traditional Chinese medicine (TCM) industry, with policies expected to enhance the TCM service system [2] - The "14th Five-Year Plan" is anticipated to further promote the development of TCM, and the company has a solid layout in the TCM industry chain [2] Group 2: Technological Innovation - The company is focusing on building a technological innovation system to address industry policies such as centralized procurement and medical insurance cost control [3] - Emphasis is placed on the development of innovative TCM drugs and the secondary development of proprietary Chinese medicines to enhance academic competitiveness and new product reserves [3] Group 3: Market Differentiation - While the market is concerned about profit declines due to centralized procurement, the company is actively enhancing marketing reforms and evidence-based medical research, which could help control expense ratios in the long term [4] - Potential catalysts include successful marketing reforms and breakthroughs in the development of new TCM drugs [4] Group 4: Profit Forecast and Valuation - The company’s EPS is projected to be -0.11 CNY, 0.06 CNY, and 0.13 CNY for 2025, 2026, and 2027 respectively [5] - The current stock price corresponds to 31.0x and 14.7x P/E for 2026 and 2027, and given the business adjustment period and the higher P/E compared to the average of Hong Kong TCM stocks, a neutral rating and a target price of HKD 2.40 is reiterated, indicating an upside potential of 11.1% [5]